Click here for an archive of Cramer's "Mad Money" Recaps.
is trying to kill the housing market, Jim Cramer said Tuesday on his "Mad Money" TV show.
That means it's time to "ring the register" on homebuilder stocks. However, the one homebuilder stock "the Fed can't crush," said Cramer, is
because it's located in Mexico.
Mi Casa Es Su Casa
Cramer acknowledged that investing in Latin America isn't without certain risks, which are "real concerns." But Cramer is willing to look past those risks because of Homex's growth.
Sales have tripled in the past two years, and the company has become more profitable as measured by return on invested capital.
Homex trades at 12 times 2006 earnings, which is in line with other Mexican homebuilders. However, he said, Homex should trade at a premium because it is the only Mexican homebuilder listed on the
New York Stock Exchange
, and its books are kept according to U.S. accounting standards.
Finally, Morgan Stanley recently initiated coverage of Homex with an overweight rating.
A caller wanted to know if Cramer was still bullish on
, another Latin American stock.
Cramer said he thought Bancolombia was still worth buying, but he wasn't as bullish on it after the stock's roughly 40% rally in the past several months.
Another caller wanted to know why Cramer was focused on Mexico. He said the country is self-sufficient in energy. Thus, its economy doesn't have the headwind of oil that the U.S. economy has.
Cramer was bullish on
Adams Respiratory Therapeutics
( ARXT). Adams, which became public last month, closed up nearly 9% Tuesday after Morgan Stanley initiated coverage of the stock with an overweight rating.
Cramer also spoke highly of the stock later in the afternoon on
his "RealMoney" radio show. Even though the stock soared, Cramer still likes it because it's a "long-term winner."
Adams, a specialty pharmaceutical company, excites Cramer because of the company's new variations of its Mucinex expectorant drug. The new variations, Cramer believes, will be granted marketing exclusivity over a number of competing drugs.
The result, he says, is that Mucinex will have the market to itself.
Cramer expects the Food and Drug Administration to grant marketing exclusivity for these new variations in the first half of 2006. If that occurs, he expects Adams' revenue to triple.
A caller asked which drug stock had the strongest pipeline and the strongest growth. "If you want to own one drug stock," Cramer said, go with
Although he's been bearish on solar power, with oil at $70 a barrel, "solar power is starting to look pretty darn nice," said Cramer. One play Cramer likes, because it doesn't have the "risk that comes from the fly-by-nighters," is
Cypress has a business unit called SunPower, which owns "perhaps the best solar power technology out there," Cramer said. SunPower's products "generate up to 50% more electricity than the competition." It's "best of breed" in the solar space.
Cypress announced this week that it would spin off SunPower but will continue to hold a controlling investment. Cypress "will still benefit from SunPower's success, but they aren't pouring money into the company to do it," Cramer said.
"From my rough math, I see at least 5 points of upside from Cypress right now."
Jumpin' Jack's Splash
CEO Paul Varga was a guest via telephone on the show. Cramer asked Varga how he was able to revitalize the company's Jack Daniel's and Southern Comfort brands.
Varga said the company drew on the strengths of the histories of the two brands and reinvented them to reach younger customers.
Cramer summed up the interview saying he was bullish on Brown-Forman because drinkers in their 20s and 30s, who used to drink Budweiser, now prefer drinks made with Southern Comfort and Jack Daniel's.
Cramer was bullish on
Martha Stewart Living Omnimedia
Procter & Gamble
Radiation Therapy Services
National Oilwell Varco
Sirius Satellite Radio
XM Satellite Radio Holdings
( XMSR) and
Cramer was bearish on
At the time of publication, Cramer was long EnCana, Yahoo! and GameStop.
James J. Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for
ActionAlertsPLUS. While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by
clicking here. Listen to Cramer's RealMoney Radio show on your computer; just click
here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click
here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click
here to get his second book, "You Got Screwed!" and click
here to order Cramer's autobiography, "Confessions of a Street Addict."